|
|
|
Cowen & Co., March 2008
Since drugs with $50 billion in 2007 U.S. sales are scheduled to lose patent/exclusivity protection in 2008-2010, the three-year period presents formidable obstacles for the pharmaceutical industry. Marketing exclusivity for several of these franchises may be extended by various means, but with a total of 70 major drugs (U.S. sales greater than $100MM annually) due to lose patent or exclusivity protection over the next five years, and several ongoing patent challenges expected to be completed in 2008-10, strong new product flow should continue to benefit the generic drug sector.
The top targets for generic drug manufacturers over the next two years include AstraZeneca’s Seroquel and Nexium, GSK’s Wellbutrin XL and Lamictal, Abbott’s Depakote ER and Prevacid, and Wyeth’s Effexor XR. A total of 23 major drugs, with combined 2007 sales of $24-$25B, could potentially lose patent and/or exclusivity protection in 2008. As in the past, however, we would expect some of these opportunities to slip into 2009-2010. Those figures slightly decrease in 2009, when 12 major drugs, with combined 2007 sales of nearly $10B, are expected to lose patent and/or exclusivity protection.
 The Industry Trend featured on this page was excerpted from
PAREXEL’s Bio/Pharmaceutical R&D Statistical
Sourcebook 2008/2009
Get your copy of the leading compendium of pharma/biotech R&D trend data and market intelligence!
400+pp! Available in Hardcopy and Electronic Access
For More information and to Order
|
Remote Data Capture:Acquisition and Analysis See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.
The Role of Analytics in Transforming Healthcare Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders. Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are: - Potentially stunning return on investment at multiple levels.
- A 500%, or better, increase in application development time by directly executing business requirements
- Improved customer retention
- A 50% possible reduction in training time
Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.
Bio-IT World & CHI
Impact of the 1000 Genomes Project on the Next Wave of Pharmacogenomic Discovery
 Interview with M. Eileen Dolan, Ph.D., Professor, Medicine, University of Chicago and Speaker at Next-Generation Sequencing Data Management, September 27-29, 2010, Providence, RI
The 1000 Genomes Project aims to provide detailed genetic variation data on >1000 genomes from worldwide populations using the next-generation sequencing technologies. Some of the samples utilized for the 1000 Genomes Project are the International Hap-Map samples that are composed of lymphoblastoid cell lines (LCLs) derived from individuals of different world populations. The detailed map of human genetic variation promised by the 1000 Genomes project will allow a more in-depth analysis of the contribution of genetic variation to drug response. Future studies utilizing this new resource can greatly enhance our understanding of the genetic basis of drug response and other complex traits.
Download Now
More Podcasts
Software Engineer – Computational Biology Center
Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.
Apply: www.mskcciscareers.org. Equal opportunity and affirmative action employer.
|
|
|